|Bid||4.33 x 900|
|Ask||4.35 x 1000|
|Day's Range||4.33 - 4.49|
|52 Week Range||3.30 - 9.90|
|Beta (3Y Monthly)||0.62|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 5, 2018 - Nov 9, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||10.00|
CAMPBELL, Calif., Oct. 10, 2018 -- VIVUS, Inc. (Nasdaq: VVUS) (the “Company”), a specialty pharmaceutical company committed to the development and commercialization of.
VIVUS, Inc. (VVUS) (the “Company”), a biopharmaceutical company that develops and commercializes novel therapeutic products to address unmet medical needs in human health, announced today that it has regained full compliance with Nasdaq listing requirements. In a letter dated September 25, 2018, Nasdaq informed the Company that it has achieved compliance with the minimum bid price rule and is in compliance with other applicable requirements required for continued listing on The Nasdaq Capital Market. “When we assembled the new management team in April, combining three new officers with the existing VIVUS team, we articulated a set of key priorities.
CAMPBELL, Calif., Sept. 24, 2018-- VIVUS, Inc.,, a biopharmaceutical company that develops and commercializes novel therapeutic products to address unmet medical needs in human health, announced today ...
VIVUS, Inc. (VVUS) (the “Company”), a biopharmaceutical company, announced today that it is supporting the Dallas-Fort Worth chapter of the Cystic Fibrosis Foundation (CFF) in its CF Climb fundraising event. This sponsorship demonstrates VIVUS’ support of the cystic fibrosis (CF) patient community as the Company launches PANCREAZE® (pancrelipase) Delayed-Release Capsules for the treatment of exocrine pancreatic insufficiency (EPI), a common complication of CF.
Shares of Vivus Inc. rallied 6.6% to trade above the $5 mark in volatile morning trade Tuesday, after the biopharmaceutical company's 1-for-10 reverse stock split went into effect. The stock has been down as much as 12% at a split-adjusted intraday low of $4.15 and up as much as 18% at a high of $5.58 since the open. The stock had closed Monday at 47 cents on a pre-split basis. Vivus Chief Executive John Amos had said it enacted the split because it determined it would position the company with the "appropriate liquidity associated with listing shares on a major U.S. exchange," which Amos said was "critical" for the execution of its strategic plan to return to profitability. One of the Nasdaq's requirements for continued listing is a minimum bid price of $1 for a company's stock. Vivus shares have tumbled 43% over the past three months, while the iShares Nasdaq Biotechnology ETF has gained 6.4% and the S&P 500 has tacked on 3.4%.
CORAL GABLES, FL / ACCESSWIRE / September 11, 2018 / Biotech stocks continue to present key drivers of returns for many investors. Public equities have delivered strong returns underpinned by large-scale of monetary policy support. It is particularly noteworthy that the California Public Employees' Retirement System is considering the creation of a direct investment program, which would include investment in companies within sectors like healthcare and biotechnology.
VIVUS, Inc. (VVUS) (the “Company”), a biopharmaceutical company, announced today that the Company’s stockholders approved a reverse stock split. Effective September 10, 2018, the Company will enact a 1-for-10 reverse stock split of its common stock with shares trading on a split-adjusted basis on September 11, 2018. “The 1-for-10 ratio was determined following an analysis of over 700 companies that effected a reverse split from 1998 to 2018.
-Retrospective analysis presented at the 34 th International Conference on Pharmacoepidemiology & Therapeutic Risk Management-. CAMPBELL, Calif., Aug. 27, 2018-- VIVUS, Inc., a biopharmaceutical company, ...
CAMPBELL, Calif., Aug. 22, 2018-- VIVUS, Inc., a specialty pharmaceutical company committed to the development and commercialization of innovative therapies focusing on treatments for patients with serious ...
In the first half of 2018, Novo Nordisk’s (NVO) human insulin generated revenues of 4.7 billion Danish kroner, a ~1% YoY (year-over-year) growth in local currencies.
The Campbell, California-based company said it had a loss of 12 cents per share. The biopharmaceutical company posted revenue of $15 million in the period. In the final minutes of trading on Tuesday, the ...
Company to host conference call today at 4:30pm ET. CAMPBELL, Calif., Aug. 07, 2018-- VIVUS, Inc., a specialty pharmaceutical company committed to the development and commercialization of innovative therapies ...
NEW YORK, NY / ACCESSWIRE / August 7, 2018 / VIVUS, Inc. (NASDAQ: VVUS ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 7, 2018 at 4:30 PM Eastern Time. To listen ...
CAMPBELL, Calif., Aug. 06, 2018-- VIVUS, Inc., a biopharmaceutical company, today announced the appointment of Ken Suh to the position of President. Suh was President and CEO of Willow Biopharma Inc., ...
CAMPBELL, Calif., July 31, 2018-- VIVUS, Inc. today announced that it will report financial results and provide a business update for the second quarter of 2018 after the market close on Tuesday, August ...
VIVUS' (VVUS) pipeline candidate, VI-0106, shows positive activity in a preliminary analysis of phase I study in patients with pulmonary arterial hypertension.
After a strong start in 2018, the drug sector struggled a bit in the next few months probably on U.S. market instability and a few negative updates on the pipeline and regulatory front. In the first four months of the year (January-April), the biotech industry significantly underperformed the S&P 500. The biotech industry declined 9.3% compared with the S&P 500’s decline of 0.8%.
Each day, the Benzinga Pro news team highlights several stocks with Trading Idea potential. Be the first to see them by becoming a Benzinga Pro user ! NANO DIMENSION/S ADR (NASDAQ: NNDM ) stock was trading ...